DSS Document Security Systems Inc.

DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market

DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market

Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in Company

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating across four distinct market sectors, announced today a significant investment by its Chairman of the Board, Heng Fai Ambrose Chan. In a strategic move to bolster shareholder confidence and underscore his commitment to the company’s growth. Chairman Chan acquired an additional 672,173 shares of DS, Inc. in an open market transaction on December 28, 2023. 

Frank Heuszel, CEO of DSS, Inc., expressed his enthusiasm for Mr. Chan's increased stake, viewing it as a strong vote of confidence in the company's strategic direction and future potential. Heuszel said, "Chairman Chan's decision to augment his investment in DSS reflects his firm belief in our vision and business plan."

The company’s growth trajectory has been particularly evident in its wholly-owned subsidiary, DSS Securities, Inc., which encompasses Sentinel Brokers and . Following a strategic expansion of its team, DSS Securities has experienced a notable increase in its Assets Under Management (AUM). This growth, coupled with the implementation of innovative marketing strategies and a steadfast commitment to creating shareholder value, positions DSS for a promising 2024.

Additionally, Heuszel highlighted the remarkable progress of Premier Packaging, another key subsidiary under the DSS umbrella. Following a substantial capital expenditure commitment, Premier Packaging has achieved impressive strides in both client retention and the acquisition of new business, further solidifying its market position and growth.

DSS, Inc.'s latest moves, spearheaded by Chairman Chan's investment and the subsidiaries' robust performance, signal a strong outlook for the company as it continues to execute its strategic business plan and explores new avenues for growth and value creation for its shareholders.

About DSS, Inc.

DSS is a multinational company operating businesses within four diversified market sectors: Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to increase shareholder value through periodic IPO spinoffs. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high-growth sectors.

For more information on DSS visit

Safe Harbor Disclosure

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company's intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in our SEC filings, including, without limitation, our reports on Forms 8-K, 10-K and 10-Q, all of which can be obtained on the SEC website at . Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

Contact:

DSS Inc. Investor Relations



+1 (585) 565-2422



EN
04/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Document Security Systems Inc.

 PRESS RELEASE

Sentinel Brokers Company, Inc., a Subsidiary of DSS, Inc., Receives FI...

Sentinel Brokers Company, Inc., a Subsidiary of DSS, Inc., Receives FINRA Approval to Act as Underwriter and Selling Group Member for Corporate Securities Offerings NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Sentinel Brokers Company, Inc. (“Sentinel”), a FINRA-registered broker-dealer and a subsidiary of DSS, Inc. (NYSE American: DSS), is pleased to announce that it has received approval from the Financial Industry Regulatory Authority (FINRA) to act as an underwriter and selling group member for corporate securities offerings. This regulatory milestone significantly enhances Sentinel’...

 PRESS RELEASE

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining...

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc. (NYSE American: IBO) in a strategic, all-equity transaction valued at approximately $1.15 million. This divestiture aligns with DSS’ ongoing strategy to optimize its portfolio and concentrate on core growth areas. Celios® is a cutting-edge air purifi...

 PRESS RELEASE

DSS, Inc. Issues Letter to Shareholders

DSS, Inc. Issues Letter to Shareholders NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) a multinational company operating businesses within diversified market sectors that strategically acquires and develops assets to increase shareholder value, today issued the following letter to shareholders: Dear Esteemed Shareholders, I am pleased to provide you with significant updates regarding the leadership of DSS, Inc. and to outline the strategic direction we are pursuing as a Company. It is with great honor that I announce my appointment as Interim Chief Executive...

DSS Inc: 1 director

A director at DSS Inc bought 1,025,746 shares at 0.975USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proud...

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol “IBO,” these shares will b...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch